{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:06:40Z","timestamp":1754194000519,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Supraventricular tachycardias (SVTs) are common in the first year of life and may be life-threatening. Acute cardioversion is usually effective, with both pharmacological and non-pharmacological procedures. However, as yet no international consensus exists concerning the best drug required for a stable conversion to sinus rhythm (maintenance treatment). Our study intends to describe the experience of a single centre with maintenance drug treatment of both re-entry and automatic SVTs in the first year of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From March 1995 to April 2019, 55 patients under one year of age with SVT were observed in our Centre. The SVTs were divided into two groups: 45 re-entry and 10 automatic tachycardias. As regards maintenance therapy, in re-entry tachycardias, we chose to start with oral flecainide and in case of relapses switched to combined treatment with beta-blockers or digoxin. In automatic tachycardias we first administered a beta-blocker, later combined with flecainide or amiodarone when ineffective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients\u2019 median follow-up time was 35\u00a0months. In re-entry tachycardias, flecainide was effective as monotherapy in 23\/45 patients (51.1%) and in 20\/45 patients (44.4%) in combination with nadolol, sotalol or digoxin (overall 95.5%). In automatic tachycardias, a beta-blocker alone was effective in 3\/10 patients (30.0%), however, the best results were obtained when combined with flecainide: overall 9\/10 (90%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this retrospective study on pharmacological treatment of SVTs under 1\u00a0year of age the combination of flecainide and beta-blockers was highly effective in long-term maintenance of sinus rhythm in both re-entry and automatic tachycardias.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-020-01843-0","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:04:18Z","timestamp":1615806258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24\u00a0years of experience in a single centre"],"prefix":"10.1186","volume":"21","author":[{"given":"Guglielmo","family":"Capponi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Belli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-6882","authenticated-orcid":false,"given":"Mattia","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Remaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vannuccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Favilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Porcedda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6112-191X","authenticated-orcid":false,"given":"Luciano","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"issue":"6","key":"1843_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.earlhumdev.2015.04.001","volume":"91","author":"PY Chu","year":"2015","unstructured":"Chu PY, Hill KD, Clark RH, Brian Smith P, Hornik CP. Treatment of supraventricular tachycardia in infants: analysis of a large multicenter database. Early Hum Dev. 2015;91(6):345\u201350.","journal-title":"Early Hum Dev"},{"issue":"4","key":"1843_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S1047951100009677","volume":"10","author":"G Vignati","year":"2000","unstructured":"Vignati G, Balla E, Mauri L, Lunati M, Figini A. Clinical and electrophysiologic evolution of the Wolff\u2013Parkinson\u2013White syndrome in children: impact on approaches to management. Cardiol Young. 2000;10(4):367\u201375.","journal-title":"Cardiol Young"},{"issue":"11","key":"1843_CR3","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/0002-9149(85)90513-2","volume":"55","author":"AS Pickoff","year":"1985","unstructured":"Pickoff AS, Singh S, Flinn CJ, McCormack J, Stolfi A, Gelband H. Atrial vulnerability in the immature canine heart. Am J Cardiol. 1985;55(11):1402\u20136.","journal-title":"Am J Cardiol"},{"key":"1843_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/europace\/eut082","volume":"15","author":"J Brugada","year":"2013","unstructured":"Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15:1337\u201382.","journal-title":"Europace"},{"key":"1843_CR5","first-page":"1809","volume-title":"The science and practice of pediatric cardiology","author":"A Ludomirky","year":"1990","unstructured":"Ludomirky A, Garson A. Supraventricular tachycardia . In: Garson A Jr, Bricker JT, McNamara DG, editors. The science and practice of pediatric cardiology. Philadelphia: Lea & Febiger; 1990. p. 1809\u201348."},{"issue":"17","key":"1843_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1053\/euhj.2002.3274","volume":"23","author":"PJ Schwartz","year":"2002","unstructured":"Schwartz PJ, Garson A, Paul T, Stramba-Badiale M, Vetter VL, Villain E, et al. Guidelines for the interpretation of the neonatal electrocardiogram: a Task Force of the European Society of Cardiology. Eur Heart J. 2002;23(17):1329\u201344.","journal-title":"Eur Heart J"},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2174\/138161208784007752","volume":"14","author":"G Vignati","year":"2008","unstructured":"Vignati G, Annoni G. Characterization of supraventricular tachycardia in infants: clinical and instrumental diagnosis. Curr Pharm Des. 2008;14:729\u201335.","journal-title":"Curr Pharm Des"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/anec.12246","volume":"20","author":"C Butt\u00e0","year":"2015","unstructured":"Butt\u00e0 C, Tuttolomondo A, Giarrusso L, Pinto A. Electrocardiographic diagnosis of atrial tachycardia: classification, P-wave morphology, and differential diagnosis with other supraventricular tachycardias. Ann Noninvasive Electrocardiol. 2015;20:314\u201327.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"5","key":"1843_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2459\/JCM.0b013e328329154d","volume":"10","author":"M Ferlini","year":"2009","unstructured":"Ferlini M, Colli AM, Bonanomi C, Salvini L, Galli MA, Salice P, et al. Flecainide as first-line treatment for supraventricular tachycardia in newborns. J Cardiovasc Med. 2009;10(5):372\u20135.","journal-title":"J Cardiovasc Med"},{"key":"1843_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/europace\/eun069","volume":"10","author":"F Drago","year":"2008","unstructured":"Drago F, Silvetti MS, De Santis A, Marcora S, Fazio G, Anaclerio S, et al. Paroxysmal reciprocating supraventricular tachycardia in infants: Electrophysiologically guided medical treatment and long-term evolution of the re-entry circuit. Europace. 2008;10:629\u201335.","journal-title":"Europace"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/pace.13662","volume":"42","author":"AC Hill","year":"2019","unstructured":"Hill AC, Silka MJ, Bar-Cohen Y. A comparison of oral flecainide and amiodarone for the treatment of recurrent supraventricular tachycardia in children. PACE Pacing Clin Electrophysiol. 2019;42:670\u20137.","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"1843_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.hrthm.2019.03.015","volume":"16","author":"A Creo","year":"2019","unstructured":"Creo A, Anderson H, Cannon B, Lteif A, Kumar S, Tebben P, et al. Patterns of amiodarone-induced thyroid dysfunction in infants and children. Heart Rhythm. 2019;16:1436\u201342.","journal-title":"Heart Rhythm"},{"key":"1843_CR13","doi-asserted-by":"publisher","first-page":"A26","DOI":"10.1016\/0002-9149(92)91074-E","volume":"70","author":"I Crozier","year":"1992","unstructured":"Crozier I. Flecainide in the Wolff\u2013Parkinson\u2013White syndrome. Am J Cardiol. 1992;70:A26\u201332.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1843_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0735-1097(89)90070-3","volume":"14","author":"JC Perry","year":"1989","unstructured":"Perry JC, McQuinn RL, Smith RT, Gothing C, Fredell P, Garson A. Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. J Am Coll Cardiol. 1989;14(1):185\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"1843_CR15","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/0002-8703(92)90081-6","volume":"124","author":"JC Perry","year":"1992","unstructured":"Perry JC, Garson A. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J. 1992;124:1622\u20134.","journal-title":"Am Heart J"},{"key":"1843_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJM198908103210629","volume":"321","author":"CAST Investigators","year":"1989","unstructured":"Investigators CAST. Effect of encainide and flecainide on mortality in a randomised trial of arrhythmia supression after myocardial infarction. N Engl J Med. 1989;321:406\u201312.","journal-title":"N Engl J Med"},{"key":"1843_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/eurheartj\/14.4.546","volume":"14","author":"G Vignati","year":"1993","unstructured":"Vignati G, Mauri L, Figini A. The use of propafenone in the treatment of tachyarrhythmias in children. Eur Heart J. 1993;14:546\u201350.","journal-title":"Eur Heart J"},{"key":"1843_CR18","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s00246-011-0010-0","volume":"32","author":"JD Knudson","year":"2011","unstructured":"Knudson JD, Cannon BC, Kim JJ, Moffett BS. High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol. 2011;32:896\u2013903.","journal-title":"Pediatr Cardiol"},{"key":"1843_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCEP.112.972620","volume":"5","author":"S Sanatani","year":"2012","unstructured":"Sanatani S, Potts JE, Reed JH, Saul JP, Stephenson EA, Gibbs KA, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circ Arrhythmia Electrophysiol. 2012;5:984\u201391.","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"1843_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacc.2003.09.031","volume":"43","author":"JC Salerno","year":"2004","unstructured":"Salerno JC, Kertesz NJ, Friedman RA, Fenrich AL. Clinical course of atrial ectopic tachycardia is age-dependent: results and treatment in children <3 or \u22653 years of age. J Am Coll Cardiol. 2004;43:438\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1843_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/0735-1097(95)00291-9","volume":"26","author":"JJ O\u2019Sullivan","year":"1995","unstructured":"O\u2019Sullivan JJ, Gardiner HM, Wren C. Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? J Am Coll Cardiol. 1995;26(4):991\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jacc.2019.06.024","volume":"74","author":"T Miyoshi","year":"2019","unstructured":"Miyoshi T, Maeno Y, Hamasaki T, Inamura N, Yasukochi S, Kawataki M, et al. Antenatal therapy for fetal supraventricular tachyarrhythmias: multicenter trial. J Am Coll Cardiol. 2019;74:874\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"1843_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0735-1097(01)01773-9","volume":"39","author":"JF Price","year":"2002","unstructured":"Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age. J Am Coll Cardiol. 2002;39:517\u201320.","journal-title":"J Am Coll Cardiol."},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1067\/mcp.2001.113795","volume":"69","author":"JP Saul","year":"2001","unstructured":"Saul JP, Ross B, Schaffer MS, Beerman L, Melikian AP, Shi J, et al. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Clin Pharmacol Ther. 2001;69:145\u201357.","journal-title":"Clin Pharmacol Ther."},{"key":"1843_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00246-016-1544-y","volume":"38","author":"JC von Alvensleben","year":"2017","unstructured":"von Alvensleben JC, LaPage MJ, Caruthers R, Bradley DJ. Nadolol for treatment of supraventricular tachycardia in infants and young children. Pediatr Cardiol. 2017;38:525\u201330.","journal-title":"Pediatr Cardiol"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0735-1097(88)90106-4","volume":"11","author":"AV Mehta","year":"1988","unstructured":"Mehta AV, Sanchez GR, Sacks EJ, Casta A, Dunn JM, Donner RM. Ectopic automatic atrial tachycardia in children: clinical characteristics, management and follow-up. J Am Coll Cardiol. 1988;11:379\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1843_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/pediatric12030024","volume":"12","author":"G Belli","year":"2020","unstructured":"Belli G, Giovannini M, Porcedda G, Moroni M, la Marca G, Capponi G, et al. Incessant automatic atrial tachycardia in a neonate successfully treated with nadolol and closely spaced doses of flecainide: a case report. Pediatr Rep. 2020;12(3):108\u201313.","journal-title":"Pediatr Rep."},{"issue":"3","key":"1843_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/bdd.1877","volume":"35","author":"A Horie","year":"2014","unstructured":"Horie A, Ishida K, Shibata K, Taguchi M, Ozawa A, Hirono K, et al. Pharmacokinetic variability of flecainide in younger Japanese patients and mechanisms for renal excretion and intestinal absorption. Biopharm Drug Dispos. 2014;35(3):145\u201353.","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"1843_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3109\/14767058.2010.509915","volume":"24","author":"MC Tavera","year":"2011","unstructured":"Tavera MC, Bassareo PP, Neroni P, Follese C, Manca D, Montis S, et al. Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma. J Matern Neonatal Med. 2011;24(3):541\u20134.","journal-title":"J Matern Neonatal Med"},{"issue":"2","key":"1843_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/0735-1097(91)90586-X","volume":"18","author":"FA Fish","year":"1991","unstructured":"Fish FA, Gillette PC, Benson DW. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol. 1991;18(2):356\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1843_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-014-0978-3","volume":"36","author":"BS Moffett","year":"2015","unstructured":"Moffett BS, Valdes SO, Lupo PJ, Miyake C, Krenek M, , et al. Flecainide use in children with cardiomyopathy or structural heart disease. Pediatr Cardiol. 2015;36(1):146\u201350.","journal-title":"Pediatr Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01843-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-020-01843-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01843-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T09:16:01Z","timestamp":1617268561000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01843-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01843-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol (entitled 001_TPSV) was approved by the ethics committee of the Anna Meyer Children\u2019s University Hospital (Florence). We obtained written informed consent from all the parents of participants in the study. All the procedures were performed in accordance with the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}